Pfizer receives positive CHMP opinion for oncology biosimilar, ZIRABEV™ (bevacizumab)

Alternative Medicine
PfizerPfizer Inc. (NYSE:PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for ZIRABEV™ (bevacizumab), a potential biosimilar to Avastin (bevacizumab).

Leave a Reply

Your email address will not be published. Required fields are marked *